Ascension® MCP Post-Approval Study

Inclusion Criteria:

• Indications consistent with the FDA approved Indications For Use: Index, long, ring, or
small finger metacarpophalangeal (MCP) joints that exhibit symptoms of pain, limited
motion, or inadequate bony alignment (i.e., subluxation/dislocation) secondary to
articular destruction or degenerative disease related to rheumatoid arthritis, systemic
lupus erythematosus, osteoarthritis, or post-traumatic arthritis where soft tissue
reconstruction can provide adequate stabilization;

- Willing to participate in the study;

- Signed an Informed Consent Form

- The means and ability to return for all required study visits; and

- Are not transient.

Exclusion Criteria:

Patients who have any of the following contraindications will be excluded from the study:

- Inadequate bone stock at the implantation site;

- Active infection in the MCP joint;

- Nonfunctioning and irreparable MCP musculotendinous system;

- Physical interference with or by other prostheses during implantation or use;

- Procedures requiring modification of the prosthesis; or

- Skin, bone, circulatory and/or neurological deficiency at the implantation site.